What we're reading, January 13, 2016: at a recent healthcare investor conference pharmaceutical company executives showed no concern over public outrage of rising drug prices; the American Hospital Association urges MedPAC withdraw 340B payment proposal; and California lawmaker reintroduces "right-to-try" bill.
Pharmaceutical executives brushed off public outrage over the high cost of drugs during presentations at the 34th annual JP Morgan Healthcare conference in San Francisco. STAT reported that Gregg Alton, the executive vice president for corporate and medical affairs at Gilead Sciences, said he sleeps quite well when he was asked how he lives with himself. An executive at the industry group BIO called public anger at drug companies “an abomination” and Gilead’s president said drug pricing concerns aren’t a real issue but a “campaign issue.”
The American Hospital Association has written to the Medicare Payment Advisory Commission (MedPAC) to urge it to withdraw recommendations to reduce drug payments to hospitals participating in the 340B Drug Pricing Program. According to the letter, the recommendation penalizes certain hospitals for being able to obtain discounts. MedPAC is expected to vote on the payment proposal later this week.
Although California Governor Jerry Brown rejected last year a bill that would let terminally patients access experimental drugs, a lawmaker intends to reintroduce the legislation. The proposal would let patients with life-threatening diseases obtain recommendation from 2 doctors so they could try drugs that haven’t yet been approved by the FDA, according to LA Times.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen